489 related articles for article (PubMed ID: 17292123)
1. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells.
Peng J; He X; Wang K; Tan W; Li H; Xing X; Wang Y
Nanomedicine; 2006 Jun; 2(2):113-20. PubMed ID: 17292123
[TBL] [Abstract][Full Text] [Related]
2. Poly(L-lysine)-modified silica nanoparticles for the delivery of antisense oligonucleotides.
Zhu SG; Xiang JJ; Li XL; Shen SR; Lu HB; Zhou J; Xiong W; Zhang BC; Nie XM; Zhou M; Tang K; Li GY
Biotechnol Appl Biochem; 2004 Apr; 39(Pt 2):179-87. PubMed ID: 15032738
[TBL] [Abstract][Full Text] [Related]
3. One-pot synthesis of sustained-released doxorubicin silica nanoparticles for aptamer targeted delivery to tumor cells.
He X; Hai L; Su J; Wang K; Wu X
Nanoscale; 2011 Jul; 3(7):2936-42. PubMed ID: 21623439
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells.
Aukunuru JV; Ayalasomayajula SP; Kompella UB
J Pharm Pharmacol; 2003 Sep; 55(9):1199-206. PubMed ID: 14604462
[TBL] [Abstract][Full Text] [Related]
5. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
Normand N; Valamanesh F; Savoldelli M; Mascarelli F; BenEzra D; Courtois Y; Behar-Cohen F
Mol Vis; 2005 Mar; 11():184-91. PubMed ID: 15761390
[TBL] [Abstract][Full Text] [Related]
6. Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture.
Wang Y; Nakamura K; Liu X; Kitamura N; Kubo A; Hnatowich DJ
Bioconjug Chem; 2007; 18(4):1338-43. PubMed ID: 17605463
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of malarial topoisomerase II in Plasmodium falciparum by antisense nanoparticles.
Föger F; Noonpakdee W; Loretz B; Joojuntr S; Salvenmoser W; Thaler M; Bernkop-Schnürch A
Int J Pharm; 2006 Aug; 319(1-2):139-46. PubMed ID: 16713146
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
9. Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids.
Wu M; Sherwin T; Brown WL; Stockley PG
Nanomedicine; 2005 Mar; 1(1):67-76. PubMed ID: 17292060
[TBL] [Abstract][Full Text] [Related]
10. A calcium phosphate nanoparticle-based biocarrier for efficient cellular delivery of antisense oligodeoxynucleotides.
Hou S; Ma H; Ji Y; Hou W; Jia N
ACS Appl Mater Interfaces; 2013 Feb; 5(3):1131-6. PubMed ID: 23323641
[TBL] [Abstract][Full Text] [Related]
11. Comparison of antisense oligonucleotide drug delivery systems.
Weyermann J; Lochmann D; Zimmer A
J Control Release; 2004 Dec; 100(3):411-23. PubMed ID: 15567506
[TBL] [Abstract][Full Text] [Related]
12. Biocompatible silica nanoparticles-insulin conjugates for mesenchymal stem cell adipogenic differentiation.
Liu D; He X; Wang K; He C; Shi H; Jian L
Bioconjug Chem; 2010 Sep; 21(9):1673-84. PubMed ID: 20735012
[TBL] [Abstract][Full Text] [Related]
13. Efficient delivery of intact phosphodiester oligonucleotides by poly-beta-amino esters.
Remaut K; Symens N; Lucas B; Demeester J; De Smedt SC
J Control Release; 2010 May; 144(1):65-74. PubMed ID: 20114066
[TBL] [Abstract][Full Text] [Related]
14. In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles.
He X; Nie H; Wang K; Tan W; Wu X; Zhang P
Anal Chem; 2008 Dec; 80(24):9597-603. PubMed ID: 19007246
[TBL] [Abstract][Full Text] [Related]
15. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
[TBL] [Abstract][Full Text] [Related]
16. On the biological activity of anti-ICAM-1 oligonucleotides complexed to non-viral carriers.
Lucas B; Van Rompaey E; Remaut K; Sanders N; De Smedt SC; Demeester J
J Control Release; 2004 Apr; 96(1):207-19. PubMed ID: 15063042
[TBL] [Abstract][Full Text] [Related]
17. [Optimal effects of liposome on antisense oligodeoxynucleotides uptake by mouse breast cancer TM40D cells and the effects of antisense oligodeoxynucleotides targeting c-erbB-2 on cell proliferation and apoptosis].
Liu XA; Fan P; Wu ZY
Zhonghua Wai Ke Za Zhi; 2004 Jul; 42(13):802-5. PubMed ID: 15363300
[TBL] [Abstract][Full Text] [Related]
18. Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPV 16 E7 oncogene.
Lappalainen K; Pirilä L; Jääskeläinen I; Syrjänen K; Syrjänen S
Anticancer Res; 1996; 16(5A):2485-92. PubMed ID: 8917339
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system.
Lavigne C; Thierry AR
Biochem Biophys Res Commun; 1997 Aug; 237(3):566-71. PubMed ID: 9299405
[TBL] [Abstract][Full Text] [Related]
20. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
Weyermann J; Lochmann D; Georgens C; Zimmer A
Eur J Pharm Biopharm; 2005 Apr; 59(3):431-8. PubMed ID: 15760723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
